Savara Pharmaceuticals
Savara Pharmaceuticals focuses on the development of an inhaled antibiotic for autoimmune pulmonary alveolar proteinosis (aPAP).
3
Funding Rounds
$16.3m
Money raised
Overview
Savara Pharmaceuticals focuses on the development of an inhaled antibiotic for autoimmune pulmonary alveolar proteinosis (aPAP).
-
Website:
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company Savara Pharmaceuticals has raised a total of $7.73m in funding over 3 rounds.
Key Insights:
- Savara Pharmaceuticals Series B round: $6.9m
- Savara Pharmaceuticals Series A round: $833k
- Savara Pharmaceuticals Series B round March 2013: $8.6m
Savara Pharmaceuticals Series B round
$6.9m
Savara Pharmaceuticals Series A round
$833k
Savara Pharmaceuticals Series B round March 2013
$8.6m
Industries
Savara Pharmaceuticals is active in the following industries: